Valuation Cumberland Pharmaceuticals Inc.

Stocks

Market Closed - Nasdaq 01:00:00 07/11/2026 +04			5-day change	1st Jan Change
5.220 ^USD	+4.19%		+11.30%	+31.16%

10-27	Cumberland Pharmaceuticals Inc. - Special Call
10-27	Cumberland Pharmaceuticals Inc. Announces Plans To Submit New Drug Application To FDA For Ifetroban As Potential Treatment For Cardiomyopathy Associated With Duchenne Muscular Dystrophy	CI

Data adjusted to current consolidation scope

Fiscal Period: December	2020	2021	2022	2023	2024	2025
Market Cap ¹	44.3	68.9	32.54	26.7	33.28	59.53
Change	-	55.54%	-52.77%	-17.94%	24.62%	78.87%
Enterprise Value (EV) ¹	36.62	57.92	33.75	26.81	35.89	58.26
Change	-	58.17%	-41.74%	-20.55%	33.85%	62.34%
P/E	-13.4x	-19.8x	-5.88x	-4.07x	-5.14x	-20.8x
PBR	0.94x	1.61x	0.89x	0.85x	1.45x	2.39x
PEG	-	-2.73x	-0.1x	-0.3x	-1.08x	0.4x
Capitalization / Revenue	1.18x	1.91x	0.77x	0.68x	0.88x	1.34x
EV / Revenue	0.98x	1.61x	0.8x	0.68x	0.95x	1.31x
EV / EBITDA	-22.4x	-18.9x	-89.6x	-21x	-23.5x	43.1x
EV / EBIT	-5.74x	-7.54x	-5.92x	-4.32x	-5.58x	-20.9x
EV / FCF	-19.5x	160x	14x	2.87x	-45x	9.05x
FCF Yield	-5.12%	0.62%	7.12%	34.8%	-2.22%	11.1%
Dividend per Share ²	-	-	-	-	-	-
Rate of return	-	-	-	-	-	-
EPS ²	-0.2202	-0.2362	-0.3825	-0.44	-0.4609	-0.1909
Distribution rate	-	-	-	-	-	-
Net sales ¹	37.44	35.99	42.01	39.55	37.87	44.52
EBITDA ¹	-1.633	-3.071	-0.3768	-1.275	-1.53	1.353
EBIT ¹	-6.382	-7.677	-5.705	-6.211	-6.432	-2.792
Net income ¹	-3.339	-3.508	-5.57	-6.279	-6.48	-2.836
Net Debt ¹	-7.677	-10.98	1.201	0.1069	2.608	-1.264
Reference price ²	2.950	4.670	2.250	1.792	2.370	3.980
Nbr of stocks (in thousands)	15,017	14,755	14,464	14,905	14,042	14,957
Announcement Date	12/03/21	11/03/22	13/03/23	13/03/24	07/03/25	09/03/26

¹USD in Million²USD

Estimates

Add to a list 0 selected To use this feature you must be a member Log in Sign up	P/E (Y)	EV / Sales (Y)	EV / EBITDA (Y)	Dividend Yield (Y)	Capi.($)
CUMBERLAND PHARMACEUTICALS INC.	-	-	-	-	78.21M
ELI LILLY AND COMPANY	39.62x	13.42x	28.51x	0.5%	1,206B
JOHNSON & JOHNSON	40.43x	6.79x	19.09x	1.93%	665B
ABBVIE INC.	37.45x	8.51x	17.57x	2.38%	515B
ROCHE HOLDING AG	20.98x	5.12x	12.74x	2.57%	381B
MERCK & CO., INC.	97.18x	5.95x	25.33x	2.32%	362B
NOVARTIS AG	23.18x	5.95x	14.36x	2.69%	307B
ASTRAZENECA PLC	24.46x	4.89x	13.77x	1.79%	289B
AMGEN INC.	23.66x	7.32x	13.53x	2.19%	249B
GILEAD SCIENCES, INC.	-39.95x	7.29x	45.82x	1.98%	207B
Average	29.67x	7.25x	21.19x	2.04%	417.98B
Weighted average by Cap.	35.62x	8.55x	21.86x	1.73%